摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

24,25-dihydroxycholesterol | 51384-93-1

中文名称
——
中文别名
——
英文名称
24,25-dihydroxycholesterol
英文别名
(24RS)-3β,24,25-Trihydroxy-cholest-5-ene;3β,24,25-trihydroxycholest-5-ene;(24RS)-3β,24,25-trihydroxycholest-5-en;(6R)-6-[(3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptane-2,3-diol
24,25-dihydroxycholesterol化学式
CAS
51384-93-1
化学式
C27H46O3
mdl
——
分子量
418.66
InChiKey
OFNJCHBCBBSWHW-SUSFDCQQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.6
  • 重原子数:
    30
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.93
  • 拓扑面积:
    60.7
  • 氢给体数:
    3
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS<br/>[FR] COMPOSÉS BENZAMIDE OU BENZAMINE À UTILISER EN TANT QU'ANTICANCÉREUX POUR LE TRAITEMENT DE CANCERS HUMAINS
    申请人:UNIV TEXAS
    公开号:WO2017007634A1
    公开(公告)日:2017-01-12
    The described invention provides small molecule anti-cancer compounds for treating tumors that respond to cholesterol biosynthesis inhibition. The compounds selectively inhibit the cholesterol biosynthetic pathway in tumor-derived cancer cells, but do not affect normally dividing cells.
    所描述的发明提供了用于治疗对胆固醇生物合成抑制作出反应的肿瘤的小分子抗癌化合物。这些化合物选择性地抑制肿瘤来源的癌细胞中的胆固醇生物合成途径,但不影响正常分裂的细胞。
  • [EN] THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER<br/>[FR] AGENTS THÉRAPEUTIQUES CIBLANT LA POLYPOSE ADÉNOMATEUSE COLIQUE (APC) MUTANTE POUR LE TRAITEMENT DU CANCER
    申请人:UNIV TEXAS
    公开号:WO2020117972A1
    公开(公告)日:2020-06-11
    The present disclosure reports an extensive medicinal chemistry evaluation of a large collection of Truncating APC-Selective Inhibitor (TASIN) compounds. The compounds were evaluated for activity against a series of colon cancer cell lines with and without truncating APC-mutations, as well as in an isogenic cell line pair reporting on the status of APC- dependent selectivity. A number of very potent and selective compounds were identified, including compounds with good metabolic stability and PK properties. The small molecules reported herein thus represent a first-in-class genotype-selective series that specifically target ape mutations present in the vast majority of CRC patients, and therefore serves as a translational platform towards a potential targeted therapy for colon cancer.
    本披露报告了对大量截断APC-选择性抑制剂(TASIN)化合物的广泛药物化学评估。这些化合物针对一系列结肠癌细胞系进行了活性评估,包括具有截断APC突变和不具有截断APC突变的细胞系,以及在报告APC依赖性选择性状况的同源细胞系对。鉴定了一些非常有效和选择性的化合物,包括具有良好代谢稳定性和药代动力学性质的化合物。因此,本文报道的小分子代表了一种首创的基因型选择性系列,专门针对存在于绝大多数结直肠癌患者中的猿类突变,因此可作为一个转化平台,朝着结肠癌的潜在靶向治疗迈进。
  • 25-Hydroxy-24-oxocholestane derivatives and preparation thereof
    申请人:Teijin Limited
    公开号:US04292249A1
    公开(公告)日:1981-09-29
    This invention relates to novel 25-hydroxy-24-oxocholestane derivatives and a process for preparing them. The novel 25-hydroxy-24-oxocholestane derivatives of this invention can easily be converted to 24,25-dihydroxycholecalciferol or 1.alpha.,24,25-trihydroxycholecalciferol which is known as useful for medicine controlling the calcium metabolism of warm-blooded animals. Moreover, 25-hydroxy-24-oxocholestane derivatives can be converted to novel 25-hydroxy-24-oxocholecalciferol expressed by the following formula ##STR1## and novel 1.alpha.,25-dihydroxy-24-oxocholecalciferol of the formula ##STR2## which are useful for medicine. The new 25-hydroxy-24-oxocholestane derivatives in the present invention are very useful as the intermediates for the synthesis of a variety of active vitamin D.sub.3.
    这项发明涉及新型的25-羟基-24-氧基胆甾烷衍生物以及其制备方法。本发明的新型25-羟基-24-氧基胆甾烷衍生物可以很容易地转化为24,25-二羟基胆钙化醇或1α,24,25-三羟基胆钙化醇,这在医学上被认为对于控制温血动物的钙代谢很有用。此外,25-羟基-24-氧基胆甾烷衍生物可以转化为由以下式表示的新型25-羟基-24-氧基胆钙化醇和由以下式表示的新型1α,25-二羟基-24-氧基胆钙化醇,这在医学上很有用。本发明中的新型25-羟基-24-氧基胆甾烷衍生物非常有用,可作为合成各种活性维生素D.sub.3的中间体。
  • Meiosis regulating compounds
    申请人:——
    公开号:US20010005757A1
    公开(公告)日:2001-06-28
    Certain compounds, structurally related to natural compounds which can be extracted i.a. from bull testes and from human follicular fluid, can be used for regulating the meiosis in oocytes and in male germ cells. Some of these compounds are useful in the treatment of infertility, whereas other compounds are useful as contraceptives. These compounds have the structural formula 1 wherein the substituents are as defined in the specification.
    某些化合物在结构上与可以从公牛睾丸和人类卵泡液中提取的天然化合物相关,可用于调节卵母细胞和男性生殖细胞中的减数分裂。其中一些化合物对治疗不孕症有用,而其他化合物则可用作避孕药。这些化合物具有结构式,其中取代基如规范中定义。
  • [EN] PROCESS FOR PREPARING 1A-HYDROXYLATED COMPOUNDS
    申请人:——
    公开号:WO1979000513A1
    公开(公告)日:1979-08-09
    (EN) The principal object of the invention is to provide a method for directly introducing an oxygen function at carbon 1 of the vitamin D molecule or precursors or derivatives thereof which comprises subjecting such molecule to allylic oxidation utilizing selenium dioxide as the oxidizing agent. It is recognized that 1(Alpha)-hydroxylation is essential to impart biological activity to vitamin D compounds and their derivatives and the present invention provides an efficient and direct method for accomplishing the desired 1(Alpha)-hydroxylation. (FR) La methode pour introduire une fonction oxygene ou carbone 1 de la molecule de la vitamine D ou de ses precurseurs ou de ses derives consiste a soumettre la molecule a une oxydation allylique en utilisant le dioxyde de selenium comme agent oxydant. Il est reconnu que l"hydroxylation en 1(Alpha) est essentielle pour donner l"activite biologique aux composes de la vitamine D et leurs derives et la methode pour l"hydroxylation en 1(Alpha) est directe et efficace.
    本发明的主要目的是提供一种方法,直接在维生素D分子或其前体或衍生物的碳1上引入氧功能,该方法包括利用亚砜二氧化物作为氧化剂对该分子进行烯丙基氧化。人们认识到,1(α)-羟基化对于赋予维生素D化合物及其衍生物生物活性是必要的,而本发明提供了一种高效且直接实现所需1(α)-羟基化的方法。
查看更多